Exelixis Inc
Exelixis Inc logo
EXEL

Exelixis Inc (EXEL)

$21.640.32%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$21.34
Day's Range
$21.82
$15.5
52-Week Range
$23.4
1 month return14.86%
3 month return6.54%
1 year return19.7%
5 year return20.44%

Company Information

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, it established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. Its discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and it has entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from its marketed products and collaborations, it is committed to prudently reinvesting in its business to maximize the potential of its pipeline. It is supplementing its existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune's 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company.
OrganizationExelixis Inc
Employees484
CEO
IndustryHealth Technology

Analyst Recommendation

based on 20 analysts ratings

Buy
80%
Buy
15%
Hold
5%
Sell

Based on 20 Wall street analysts offering stock ratings for Exelixis Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 49.88%

Current

$21.57

Target

$32.33

Recommendation Trend

Based on 20 analyst

Current1M Ago3M Ago
Buy
16
16
16
Hold
3
3
3
Sell
1
1
1
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
7.2B
Book Value
6.93
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
0.72
PE Ratio
31.3889
PEG Ratio
0.76
Wall Street Target Price
27.17

Valuation

Trailing PE31.39
Forward PE26.25
Price/Sales (ttm)
5.04
Price/Book (mrq)
3.25
Enterprise Value
5.8B
Enterprise Value/Revenue
4.02
Enterprise Value/Ebitda
19.19

Technicals

Beta
0.78
50 Day MA
21.4
200 Day MA
19.42

Institutional Holdings

BlackRock Inc

10.06%

Vanguard Group Inc

9.44%

FMR Inc

5.36%

Renaissance Technologies Corp

5.26%

T. Rowe Price Associates, Inc.

4.92%

JPMorgan Chase & Co

3.76%

Discover more

Frequently Asked Questions

What is Exelixis Inc share price today?

Can Indians buy Exelixis Inc shares?

How can I buy Exelixis Inc shares from India?

Can Fractional shares of Exelixis Inc be purchased?

What are the documents required to start investing in Exelixis Inc stocks?

What are today’s High and Low prices of Exelixis Inc?

What are today’s traded volumes of Exelixis Inc?

What is today’s market capitalisation of Exelixis Inc?

What is the 52 Week High and Low Range of Exelixis Inc?

How much percentage Exelixis Inc is down from its 52 Week High?

How much percentage Exelixis Inc is up from its 52 Week low?

What are the historical returns of Exelixis Inc?

Who is the Chief Executive Officer (CEO) of Exelixis Inc?